SAGE 421
Alternative Names: SAGE-421Latest Information Update: 13 Apr 2023
At a glance
- Originator SAGE Therapeutics
- Class Neuroprotectants; Nootropics; Small molecules; Sterols
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cognition disorders
- Preclinical Neurodevelopmental disorders
Most Recent Events
- 12 Apr 2023 Phase-I clinical trials in Cognition disorders (PO) (SAGE Therapeutics pipeline, April 2023)
- 11 Feb 2022 Preclinical trials in Cognition disorders in USA (PO) (Sage Therapeutics pipeline, February 2022)
- 11 Feb 2022 Preclinical trials in Neurodevelopmental disorders in USA (PO) (Sage Therapeutics pipeline, February 2022)